

Curriculum Vitae		
1	Name :	Waranya RattanaVIPapong
2	Position :	Head of HITAP International Unit
3	Office :	Health Intervention and Technology Assessment Program (HITAP) 6th Floor, 6th Building, Department of Health, Ministry of Public Health, Tiwanon Road, Nonthaburi 11000
	Contact :	Tel: +662 590 4549, +662 590 4374-5 Fax: +662 590 4369
	E-mail :	waranya.r@hitap.net

4	<u>EDUCATION</u>		
	■ Year	2014	MSc. Health Economics and Decision Modelling
	Institute of graduation	The University of Sheffield, UK	
	■ Year	2008	B.Pharm Clinical and Social Pharmacy
	Institute of graduation	Srinakharinwirot University, Thailand	

5	<u>WORK EXPERIENCES</u>		
	■ 2015-PRESENT	Position	Head of HITAP International Unit
		Organization name	HITAP
	■ FEBRUARY 2010 – 2015	Position	Researcher
		Organization name	HITAP
	■ AUGUST 2008 – FEBRUARY 2010	Position	Pharmacist
		Organization name	Department of Medical Sciences, Ministry of Public Health
	■ APRIL – AUGUST 2008	Position	Pharmacist
		Organization name	King Chulalongkorn Memorial Hospital

6	<u>RESEARCH</u>	
	Principal investigator	
	1. Cost-utility and budget impact analyses of sofosbuvir-based regimens for treatment of hepatitis C virus in Thailand.	
	2. Economic evaluation of WHO Package of Essential Non-communicable disease (PEN) interventions in Indonesia.	
	3. Reviewing the evidence of HIV screening in general population (Under the project of the development of a population-based screening package in Thailand).	
	4. An economic evaluation of HLA-B*1502 genotyping in carbamazepine induced Stevens-Johnson	

	Syndrome or Toxic Epidermal Necrolysis.
	5. Formulating policy recommendations to alleviate health problems among people living around industrial areas in Thailand: a case study of leukemia.
	Co-investigator
	6. Developing evidence to inform to health benefits package in Vietnam.
	7. An economic evaluation based on a pilot of a Package of Essential Non-communicable disease (PEN) interventions in Bhutan.
	8. Reviewing economic evaluations conducted in low- and middle-income countries: information for reference case development.
	9. An economic evaluation of selected health promotion programs under Thai Health Promotion Foundation.
	10. Cost-utility analysis of 7-, 10- and 13-valent pneumococcal conjugate vaccine in Thailand.
	11. Evaluation of the National Essential Drug List Category E2 2008.
7	<u>ACADEMIC JOURNAL</u>
	1. Adeagbo CU, RattanaVIPapong W , Guinness L, Teerawattananon Y. The Development of the Guide to Economic Analysis and Research (GEAR) Online Resource for Low-and Middle-Income Countries' Health Economics Practitioners: A Commentary. Value in Health. 2017 Nov 10.
	2. Singh D, Luz AC, RattanaVIPapong W , Teerawattananon Y. Designing the Free Drugs List in Nepal: A Balancing Act Between Technical Strengths and Policy Processes. MDM Policy & Practice. 2017 Feb;2(1).
	3. Thiboonboon K, Santatiwongchai B, Chantarastapornchit V, RattanaVIPapong W , Teerawattananon Y. A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines. Applied Health Economics and Health Policy. 2016; 14(6):659-72.
	4. RattanaVIPapong W , Luz ACG, Kumluang S, Kusumawardani N, Teerawattananon Y. One step back, two steps forward: an economic evaluation of the PEN program in Indonesia. Health Systems & Reform. 2016; 2(1): 84-98.
	5. Santatiwongchai B, Chantarastapornchit V, Wilkinson T, Thiboonboon K, RattanaVIPapong W , Walker DG, et al. Methodological Variation in Economic Evaluations Conducted in Low-and Middle-Income Countries: Information for Reference Case Development. PLoS ONE. 2015; 10(5): 1-15.
	6. Dukpa W, Teerawattananon Y, RattanaVIPapong W , Srinonprasert V, Tongsri W, Kingkaew P, et al. Is diabetes and hypertension screening worthwhile in resource-limited settings? An economic evaluation based on a pilot of a Package of Essential Non-communicable (PEN) disease interventions in Bhutan. Health Policy and Planning. 2014: 1-12.
	7. RattanaVIPapong W , Koopitakkajorn T, Praditsitthikorn N, Mahasirimongkol S, and Teerawattananon Y. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia. 2013; 54(9):1628–1638.
	8. RattanaVIPapong W and Teerawattananon Y. Models of HIV counseling and testing service for general population: a review. Journal of Health Systems Research, 2013; 7(4): 452-61.
	9. Kulpeng W, Sornsrivichai V, Chongsuvivatwong V, RattanaVIPapong W , Leelahavarong P, Cairns J, Lubell Y, Teerawattananon Y. Variation of health-related quality of life assessed by caregivers and

	patients affected by severe childhood infections. BMC Pediatrics. 2013; 13(1): 122.
	10. Kulpeng W, Leelahavarong P, <u>RattanaVIPapong W</u> , Sornsrivichai V, Baggett HC, Meeyai A, et al. Cost-Utility Analysis of 10- and 13-Valent Pneumococcal Conjugate Vaccines: Protection at What Price in the Thai Context?. Vaccine. 2013; 31(26): 2839-47.
	11. Turongkaravee S, <u>RattanaVIPapong W</u> , Khampang R, Leelahavarong P, Teerawattananon Y, and Tantivess S. Increasing access to high-cost medicine under the 2008 National List of Essential Medicines (NLEM): from policy to practice. Journal of Health Systems Research, 2012; 6(3): 382-94.
	12. <u>RattanaVIPapong W</u> , Siriweeraraj J, Leelahavarong P, Teerawattananon Y. Societal Costs of Health Impact of People Living in Industrial area and their Perimeters with Risk of Acute Myeloid Leukemia. Journal of Health Science, 2012; 21:224-36.
8	<u>OTHER WORKS</u>
	<ul style="list-style-type: none"> Teerawattananon Y, <u>RattanaVIPapong W</u>, Santatiwongchai B, Bussabawalai T, Thi boonboon K, Dabak S. Chapter 17 More Than A List: Reforming a Country's Health Benefit Package-- A Rigorous Approach to Tackle Costly Overutilization. In Glassman A, Giedion U, and Smith P (editors). What's In, What's Out: Designing Benefits for Universal Health Coverage. Washington D.C. Brookings, 2017.
9	<u>TRAINING COURSES</u>
	COURSES / ORGANIZED BY
<ul style="list-style-type: none"> 2011 	Health Technology Assessment: From Theory to Evidence to Policy Workshop & Forum, Ontario, Canada, October 18-21, 2011.
<ul style="list-style-type: none"> 2015 	Workshop to Review and Train Trainers on Influenza Health Economic Tools and Guidance, Geneva, Switzerland, July 7-8, 2015.